Buy Rating for Ovid Therapeutics Based on Novel SE Drug Candidates OV329 and OV350
Ovid Therapeutics Analyst Ratings
Buy Rating for Ovid Therapeutics Based on Promising Drug Trials and Strategic Partnerships
TD Cowen Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)
Ovid Therapeutics Analyst Ratings
Citigroup Maintains Neutral on Ovid Therapeutics, Lowers Price Target to $3.5
Ovid Therapeutics Analyst Ratings
B. Riley Securities Initiates Ovid Therapeutics With Buy Rating, $9 Price Target
Ovid Therapeutics Analyst Ratings
Ovid Therapeutics Analyst Ratings
Ovid Therapeutics: Strong Buy Rating on Robust Pipeline and Strategic Partnerships
TD Cowen Sticks to Its Buy Rating for Ovid Therapeutics (OVID)
BTIG Keeps Their Buy Rating on Ovid Therapeutics (OVID)
Ovid Therapeutics (OVID) Receives a Buy From BTIG
Analysts' Top Healthcare Picks: Relay Therapeutics (RLAY), Ovid Therapeutics (OVID)
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV), Beyond Air (XAIR) and Ovid Therapeutics (OVID)
Oppenheimer Sticks to Its Buy Rating for Ovid Therapeutics (OVID)
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Ovid Therapeutics (OVID) and Crinetics Pharmaceuticals (CRNX)
Oppenheimer Initiates Coverage on Ovid Therapeutics With Outperform Rating, $8 Price Target
Promising R&D Developments and Strategic Innovation Bolster Buy Rating for Ovid Therapeutics: An Analysis
No Data